Patient Information Leaflet definition

Patient Information Leaflet means any patient information leaflet included in a pack with the medication prescribed, administered and supplied to appropriate Eligible Patients by the Registered Medical Practitioner in the provision of the Service.
View Source
Patient Information Leaflet means the information pertaining to a medicine as provided for in regulation 12, written in a manner which is easily understandable by the patient;
View Source

Examples of Patient Information Leaflet in a sentence

  • The pharmacist must ensure that the patient is advised how to take/use the medication and is provided with a Patient Information Leaflet at all times.

  • To determine expectedness of an adverse event, the local approved Summary of Product Characteristics (SPC) or, if this is not available, local approved Patient Information Leaflet, is to be used.

  • The pharmacy contractor will supply a Patient Information Leaflet (PIL) with all medication at every issue to ensure all relevant information is available should the patient or care provider require it.

  • The mechanism of action and expected effects and side effects and duration of therapy should be explained to the patient using the NRP (or equivalent) Patient Information Leaflet.

  • Each Party shall, as soon as reasonably practicable after the same become available (to the extent that such Party is undertaking any preparation of the same), provide the other Party with copies of the summary of product characteristics (the “SmPC”), the Core Data Sheet (“CDS”) and the Patient Information Leaflet (“PIL”) that are proposed or approved for the Commercialization and Development of the Product in the Field in the Territory.

  • Additionally, the MedLIS Patient Information Leaflet will be available in GP practices, and on the HSE Website.

  • Each party shall ensure that all new and returning patients are given a copy of the MedLIS Patient Information Leaflet (Appendix A) when they attend their hospital (following implementation by that hospital) for their treatment and care.

  • Advice & Follow up:  Discuss side-effects and administration with patient and provide a manufacturers Patient Information Leaflet (PIL)  Advise patient that the infection can spread therefore need to wash hands before and after touching eyes and not to share towels, pillows etc.

  • Renal function and electrolytes every six months and more often during periods of illness • Consider referral where any significant decrease in renal function is noted • Record blood pressure and heart failure symptoms The Patient Information Leaflet for Entresto® should be provided to the patient at the point of dispensing.

  • Patient Information Leaflet available via: ▇▇▇▇://▇▇▇.▇▇▇▇▇▇▇▇▇.▇▇▇.▇▇/emc/search/sildenafil Refer to manufacturer’s SPC for full prescribing information - ▇▇▇▇://▇▇▇.▇▇▇▇▇▇▇▇▇.▇▇▇.▇▇/emc/search/sildenafil 1.0 Dec16 Dr ▇ ▇▇▇▇▇, ▇▇ ▇ ▇ ▇▇▇▇▇▇▇, Rheumatology Department, Norfolk & Norwich University Hospitals NHS Foundation Trust Draft For consideration by the Therapeutics Advisory Group (TAG) – January 2017.

Related to Patient Information Leaflet

  • Patient Information means information (however recorded) which—

  • Client Information means any data, information, software or other materials that you provide to Red Hat under the Agreement.

  • Patient identifying information means an insured's address, telephone number, facsimile number, electronic mail address, photograph or likeness, employer, employment status, social security number, or any other information that is likely to lead to the identification of the insured.

  • Biometric information means any information, regardless of how it is captured, converted, stored, or shared, based on an individual’s biometric identifier used to identify an individual. Biometric information does not include information derived from items or procedures excluded under the definition of biometric identifiers.

  • Promotion of Access to Information Act ’ means the Promotion of Access to Information Act, 2000 (Act No. 2 of 2000);